Tag: Insurance Broker

SelectQuote (SLQT) – Taking Steps for the Long Term

Posted on by cpereira@noblefcm.com


Monday, September 16, 2024

Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Strong fiscal Q4. SelectQuote’s fiscal Q4 revenue of $307.2 million and adj. EBITDA of $14.4 million exceeded our estimates of $271.3 million and a loss of $2.2 million, respectively.  In our view, the strong performance demonstrated the power of the company’s synergistic business model, which serves consumers’ needs both for insurance policies and pharmacy services. 

Pharmacy momentum. Total revenue grew an impressive 38% over the prior year period, driven largely by the company’s Healthcare Services segment, which is comprised primarily of SelectRx (home-direct pharmacy business). Healthcare Services revenue was up roughly 75%, year-over-year with SelectRx membership growing to approximately 82,000, up from roughly 75,000 at the end of fiscal Q3. 


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

SelectQuote (SLQT) – Fiscal Q3 Beat; Strategic Initiatives Paying Off

Posted on by cpereira@noblefcm.com


Friday, May 10, 2024

Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Impressive results. The company reported fiscal Q3 revenue of $376.4 million, beating our estimate of $341.8 million. Adj. EBITDA in the quarter was $46.6 million, also beating our estimate, which was $40.3 million. The robust 26% revenue growth was driven primarily by Pharmacy revenue, which grew 80% over the prior year period.

Strong OEP. Revenue from the Senior segment was 20% better than our estimate, indicating a favorable Medicare Advantage Open Enrollment Period for the company. Notably, Senior segment adj. EBITDA margins were 30% in the quarter.   


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

GoHealth, Inc. (GOCO) – Q1 Illustrates Business Model Integrity

Posted on by cpereira@noblefcm.com


Friday, May 10, 2024

Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q1 results. The company reported Q1 revenue of $185.6 million, in line with our estimate of $183.0 million. Adj. EBITDA of $26.9 million was below our forecast of $30.4 million. Management indicated that market dynamics in Q1, which featured the Medicare Advantage Open Enrollment Period, were fairly consistent with the Annual Enrollment Period in Q4.

Demonstrating model integrity. During the quarter, the company reaffirmed 94,000 health insurance policies, even though such outcomes do not generate incremental revenue for the company. In our view, this serves to highlight the company’s commitment to putting the consumer first and we believe the company could be rewarded for this in the long run.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

GoHealth, Inc. (GOCO) – Highlights from Noble Virtual Conference; Building Loyalty

Posted on by cpereira@noblefcm.com


Monday, May 06, 2024

Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Noble Virtual Conference. On April 18, GoHealth CEO, Vijay Kotte, presented at Noble’s Virtual Healthcare Equity Conference. Mr. Kotte discussed several important topics, including GoHealth’s consumer-centric Medicare policy platform, additional revenue opportunities, and the company’s large addressable market. The presentation replay is available here.

Built for purpose technology. Mr. Kotte highlighted the company’s process of using proprietary technology together with its licensed agents to make recommendations for consumers based on their unique needs. Notably, individual Medicare consumers have 40-50 plan options on average, making the company’s machine learning technology an important tool in narrowing down the options to the best available.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

SelectQuote (SLQT) – Highlights from Noble Virtual Conference; Synergistic Business Model Driving Favorable Growth

Posted on by cpereira@noblefcm.com


Friday, May 03, 2024

Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Noble Virtual Conference. On April 17, management presented at Noble’s Virtual Healthcare Equity Conference. Management highlighted several key attributes of the company, such as its strong customer acquisition capabilities, synergistic business model, and long history of serving American consumers, among others.

Understanding the customer. Through its licensed agents, SelectQuote has roughly 30k conversations per day with American seniors, resulting in deep insights into the needs of American consumers, such as Medicare beneficiaries. This allows the company to refine its offerings in ways that add value for customers and lead to return customers.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

GoHealth, Inc. (GOCO) – Resetting Expectations: Still Well Positioned

Posted on by cpereira@noblefcm.com


Friday, March 15, 2024

Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q4 results below expectations. The company reported Q4 revenue of $276.7 million, 23.6% below our forecast of $362.0 million. Adj. EBITDA in the quarter was $57.0 million, below our forecast of $116.1 million. The weaker than expected results were due in large part to low Medicare Advantage plan turnover, which limited the total revenue from new policy sales in the quarter.


Low plan turnover. Management noted that the average incremental benefits added to Medicare Advantage plans in 2023 was lower than usual, which resulted in less plan switching by Medicare Advantage enrollees. Of the more than 300,000 consumers it served, GoHealth’s PlanFit Checkup recommended that roughly 1/3 of them stay with their existing plans.     


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

GeoVax Labs (GOVX) – FY2023 Reported With A Review Of Clinical Progress and Upcoming Milestones

Posted on by cpereira@noblefcm.com


Friday, March 01, 2024

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for solid tumor cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine targeting high-risk immunocompromised patient populations. Currently in three Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, and as a booster vaccine in patients with chronic lymphocytic leukemia (CLL). In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades.

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Full Year Loss Was Less Than Expected. GeoVax reported a FY2023 loss of $26.0 million or $(14.29) per share, adjusted for a 1-for-15 reverse split in January 2024. The loss for 4Q23 was $7.6 million or $(4.29) per share, compared with our estimated loss of $9.0 million. Cash on December 31 was $6.5 million. On its quarterly conference call, the company reviewed progress in its clinical programs and confirmed milestones for 2024.

Gedeptin Program Is Moving Forward. In July 2023, GeoVax reported initial data from the Phase 1/2 trial testing Gedeptin head and neck cancer. The data showed successful delivery of the PNP gene, with safety, tumor reduction, and stable disease. Enrollment was completed in 2Q23, with additional results expected in 1H24. Expansion of Phase 2 of trial is planned during 2024. Additional trials using Gedeptin as a neoadjuvant at earlier stages of disease or in combination with immune checkpoint inhibitors may be added.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

SelectQuote (SLQT) – Can It Cut Loose Its Heavy Debt Anchor?

Posted on by cpereira@noblefcm.com


Thursday, February 29, 2024

Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Initiating coverage with an Outperform rating and $5 price target. SelectQuote (NYSE: SLQT) is an insurance distribution and healthcare services organization, which is positioned to benefit from a growing population of Medicare beneficiaries. In our view, the company’s unique combination of health insurance distribution and home-direct pharmacy services represents an opportunity to drive high value per customer in a cost efficient manner. Our favorable rating reflects a strong revenue growth outlook with improving cash flow generation. 

Synergistic business model. The company’s health insurance distribution (primarily Medicare Advantage policies) and home-direct pharmacy businesses largely share a target customer base. This allows the company to economize on customer acquisition costs for its two largest segments. Taken together, the two business segments generated a revenue/customer acquisition cost (CAC) multiple of 4.2x over the trailing 12 months (as of December 31, 2023). 


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

GoHealth, Inc. (GOCO) – Initiating Coverage: An Encompassing Solution To Improve The Medicare Marketplace

Posted on by cpereira@noblefcm.com


Tuesday, January 16, 2024

Gregory Aurand, Senior Vice President, Equity Research Analyst, Healthcare Services & Medical Devices, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Large Growing Complex Medicare Market. About 66.4 million Americans were covered by Medicare in calendar 2022 and the Medicare 65 and older population is expected to reach more than 93 million people by 2060.  GoHealth has already helped 10 million Americans and seeks to be the consumer Medicare health plan destination in this growing market. As the market grows more complex with a greater number of plan offerings, GoHealth’s platform simplifies the annual Medicare private plan shopping process.

Proprietary Offering Platform. GoHealth is driving growth in the Medicare Advantage and Medicare Supplemental markets through its pressure-free unbiased consumer-centric Encompass Solution platform that utilizes its proprietary data machine-learning PlanFit Checkup technology.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.